CClinicalTrials.gg
RecruitingNCT06412822Updated May 14, 2024

Neutrophil Extracellular Traps (NET's) in Prevalent Kidney Stone

An observational study in Kidney Stone, sponsored by Brugmann University Hospital. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-14.

Sponsored by Brugmann University Hospital · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 9 months ago, but the record still lists the study as recruiting.
  • Started Sep 2023; still recruiting 3 years later.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Study summary

Neutrophils are first responders to any kind of threat the body faces: infection, severe trauma, cancer, surgery... They produce the cytokines, induct oxidative stress and de-granulate toxic proteins to kill pathogens. However the new mechanism related to the neutrophil extracellular traps release has been recognized as a new way of cell necrosis and has been called a NETosis.

NETosis is a hugely important new mechanism of human immune responses also described in various forms of acute kidney injury (ischemic, toxic, autoimmune). In certain kidney diseases, neutrophils release NETs and induce cell necrosis. Whether neutrophils die along with NET release, and if they do die, remains under study and is most likely context dependent. Extracellular traps (ETs) can be released also by macrophages. The ETs formation as well as macrophages extracellular traps (MET's) especially in kidney disease are cytotoxic and elicit inflammation, contributing to necro-inflammation of the early-injury phase of acute tubular necrosis in anti-neutrophil cytoplasmic antibody-related renal vasculitis, anti-glomerular basement membrane disease, lupus nephritis. Finally, acute kidney injury-related releases of dying renal cells or ETs promote organ injuries - for example, acute respiratory distress syndrome. According to the recent review the term 'NET formation' has been proposed as a better term to use instead of 'NETosis'. The formation of neutrophil extracellular traps (NETs) has been recently recognized as a unique modality of pathogen fixation (sticky extracellular chromatin) and pathogen killing (cytotoxic histones and proteases) during host immune responses, as well as collateral tissue damage.

Histones are potent mediators of injury in various cells. Indeed, extracellular histone induce microvascular endothelial cells and renal epithelial cells death in vitro, forms the pores that disrupt cell integrity and induce the cytolysis by their capacity of binding with membrane phospholipids and activation of inflammasome in the kidney leading to auto-entrainment of inflammation.

The activation of inflammation has been demonstrated in the experimental model of crystalline nephropathy related to the uncontrolled oxalate urinary excretion. Inhibition of inflammasome activation has been related with the preservation of kidney function. In patients with kidney stone disease the presence of crystals in the urine has been demonstrated to induce tubular epithelial cells injury that can theoretically trigger the NET's or MET's release and tissue inflammation.

NETs are now increasingly described as new targets for therapies, however largely under-estimated.

The role of release of ETs from neutrophils and macrophages during the kidney stone disease has never been studied in urine but the neutrophil extracellular trap (NET) formation-NETosis - was found significantly increased in the papillae of patients with brushite stones compared with CaOx stones.

The key objectives of this study are:

  1. to assess NET/MET's excretion in the urine as a non-invasive method of NET/MET'osis measurement in patients with kidney diseases as a new biomarker of early stage of cells damages reflecting kidney injury occurring in patients with uncontrolled stones and other renal diseases;
  2. to compare the NET/MET's concentrations in the urine with those in plasma
02

Conditions studied

  • Kidney Stone
03

In context

Kidney Calculi

598 studies on the registry are indexed under Kidney Calculi; 163 are open to participants now.

This study's planned enrollment of 500 is above the median of 144 across 110 observational studies indexed under Kidney Calculi.

Browse Kidney Calculi studies →

Lead sponsor

Brugmann University Hospital is the lead sponsor of 116 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with acute and/or chronic kidney disease, with stones or without stones, ambulatory or hospitalized in CHU Brugmann Brugmann.

Inclusion criteria

  • Patients with acute and/or chronic kidney disease, with stones or without stones, ambulatory or hospitalized in CHU Brugmann Brugmann.

Exclusion criteria

Exclusion Criteria:

  • Malignancy or treatment for malignancy within 12 months prior to Screening with the exception of localized basal cell or squamous cell skin cancer. Note: Subjects whose malignancy is in remission and who are on a stable dose of chronic suppressive or maintenance therapy are not excluded.
  • Psychological illness or condition, interfering with the patient's compliance or ability to understand the requirements of the study.
  • Participation in another clinical trial.
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • STONE group

    Adult subjects with kidney stones disease

    Other: Blood sampling · Other: Urine sampling

  • NON STONE group

    Control group: patients with acute and/or chronic kidney disease (CKD) without stones

    Other: Blood sampling · Other: Urine sampling

Interventions

  • OtherBlood sampling

    Blood sampling

  • OtherUrine sampling

    Urine sampling

06

What researchers measure

Primary outcomes

  1. Neutrophil extracellular traps (NETs) excretion in 24h urine collection

    Assessment of NET excretion in 24h urine collection

    Time frame: 24 hours

  2. Neutrophil extracellular traps (NETs) excretion in fasting urine

    Assessment of NET excretion in fasting urine

    Time frame: 24 hours

  3. Neutrophil extracellular traps (NETs) excretion in 2e morning urine

    Assessment of NET excretion in 2e morning urine

    Time frame: 24 hours

  4. Macrophages extracellular traps (MET's) excretion in 24h urine collection

    Assessment of MET's in 24h urine collection

    Time frame: 24 hours

  5. Macrophages extracellular traps (MET's) excretion in fasting urine

    Assessment of MET's in fasting urine

    Time frame: 24 hours

  6. Macrophages extracellular traps (MET's) excretion in 2e morning urine

    Assessment of MET's in 2e morning urine

    Time frame: 24 hours

Secondary outcomes

  1. Neutrophil extracellular traps (NETs) plasma levels

    Neutrophil extracellular traps (NETs) plasma levels

    Time frame: 24 hours

  2. Macrophages extracellular traps (MET's) plasma levels

    Macrophages extracellular traps (MET's) plasma levels

    Time frame: 24 hours

07

Study locations

1 of 1 sites recruiting
  • CHU Brugmann
    Brussel, 1020, Belgium
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06412822
Lead sponsor
Brugmann University Hospital
Responsible party
Agnieszka Pozdzik (Nephrologist, Brugmann University Hospital) — Principal investigator
First posted
May 14, 2024
Start date
Sep 12, 2023
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
May 14, 2024

Study contacts

Agnieszka POZDZIK
Contact
Agnieszka.POZDZIK@chu-brugmann.be
3224752639
Agnieszka POZDZIK
principal investigator · CHU Brugmann

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion